Trouble sleeping? Austin sleep apnea trial could help transform lives and treatment options
For years, Michelle Strickland had trouble sleeping – she woke up several times at night – and it left her with daytime sleepiness and her body craving lots of naps. Strickland recently went ...
Stifel maintains ResMed stock hold rating, $250 target
Stifel analysts maintained a Hold rating on ResMed stock (NYSE:RMD) with a consistent price target of $250.00. The decision comes after reviewing the company's financial performance for the second ...
Q2 2025 Resmed Inc Earnings Call
Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...
ResMed Inc. (NYSE:RMD) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript January 30, 2025 ResMed Inc. beats earnings expectations. Reported EPS is $2.43, expectations were $2.32. Operator: Welcome to the Q2 Fiscal Year 2025 ResMed Earnings ...
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets
Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...
ResMed targets 59-60% gross margins and expanded global reach for AirSense 11
CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, including AirSense 10 and ...